Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks ...

When Novartis announced it was teaming up with ... “Our approach goes beyond a focus on a single product or therapeutics to emphasize long-term, proactive behaviors that drive improved health ...

The results of those studies should start to emerge in 2025. Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in ...

as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late ...

JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq: LGND) and Channel Therapeutics ...

It is the generic version of Mekinist, a branded product developed by Novartis Pharma AG (NYSE:NVS). As part of the deal, Hikma also entered into a commercial agreement with Novugen under which it ...

Unfortunately, what's good news for Eli Lilly is probably bad news for investors in Novo Nordisk and Viking Therapeutics, both of which lag Lilly in the race to develop their own easy-to-take GLP ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $157.00. The company’s ...

Affini-T Therapeutics, Novartis, Coherus BioSciences, D3 Bio, Synthekine, Gilead Sciences, and Seagen. Wong reported no relevant relationships with industry. Source Reference: Pecci F, et al ...

Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer The following represents disclosure information provided ...